If you’ve been to a supermarket lately, you’ve probably noticed that food prices are soaring. And that spells an opportunity for investors. Asset-management expert John Stephenson offers tips for small investors aiming to tap i…
This little-known biopharmaceutical outfit has signed not just one but seven partnership pacts with Big Pharmas to help develop some of its products. Micromet’s No. 1 appeal: It’s developing novel antibody-based drugs to treat …
Paris-based pharma Sanofi-Aventis has pushed back its offer deadline for Massachusetts-based biotech Genzyme by six weeks. All other terms, including the $69 per share bid, remain unchanged. So far, very few shareholders have r…
As part of its efforts to expand into the biotech market, Johnson & Johnson is making a long-anticipated bid for Dutch vaccine maker Crucell — in spite of Crucell’s recent manufacturing troubles.
Continue read…
Much like Dendreon, which has a promising prostate cancer drug, ImmunoCellular is developing a cancer drug. In this case, it battles brain cancer, and a Phase I trial turned in remarkable results. But unlike Dendreon, ImmunoCel…